SCHEMBL2660419

SCHEMBL2660419

Clc1cccnc1Oc1ccc2ncnc(Nc3cc[nH]n3)c2c1

nearest known ligand 0.68

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
GCK P35557 13/20 0.68
EGFR P00533 3/20 0.43
MAPT P10636 1/20 0.42
GRM1 Q13255 1/20 0.42
DYRK1A Q13627 1/20 0.40
SRC P12931 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2642335 0.86 GCK (0.71) GCKEGFRMAPTGRM1
SCHEMBL2642190 0.85 GCK (0.67) GCKEGFRMAPTGRM1SRC
SCHEMBL2660082 0.82 GCK (0.68) GCKEGFRMAPTGRM1
SCHEMBL2660365 0.81 GCK (1.00) GCKEGFR
SCHEMBL2642697 0.80 GCK (0.60) GCKEGFRMAPTGRM1DYRK1A
SCHEMBL2642443 0.79 GCK (0.62) GCKEGFRMAPTGRM1
SCHEMBL2643149 0.79 GCK (0.65) GCKEGFRMAPTGRM1
SCHEMBL2642606 0.79 GCK (0.75) GCK
SCHEMBL2642310 0.78 GCK (0.43) GCKEGFRMAPTDYRK1A
SCHEMBL2642410 0.77 GCK (0.59) GCKEGFRMAPTGRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7687502-B2 Substituted quinazoline or pyridopyrimidine derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-03-30 US disclosed
US-7687502-B2 Substituted quinazoline or pyridopyrimidine derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-03-30 US disclosed
US-20080032996-A1 Substituted Quinazoline or Pyridopyrimidine Derivative MSD K.K. (JP) 2008-02-07 US disclosed
US-20080032996-A1 Substituted Quinazoline or Pyridopyrimidine Derivative MSD K.K. (JP) 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080032996-A1 Substituted Quinazoline or Pyridopyrimidine Derivative GCK, GCKR, PDXK GCK 1/4885EGFR 3484/4885MAPT 4375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.